Skip to main content
Premium Trial:

Request an Annual Quote

Peter Ehrenheim, William Clarke, Mark Schmeizl, Bernard Questier, and Anthony Martin

Premium

GE Healthcare Biosciences has named Peter Ehrenheim president of protein separations, a role he initially assumed for Amersham in 1999. He has served as vice president for North American manufacturing for Amerhsam Pharmacia Biotech. He holds an MSc in mechanical engineering from the Royal Institute of Technology in Stockholm, Sweden.

GE Healthcare has also appointed William Clarke as vice president and chief technology and medical officer. Clarke served as executive vice president of research and development at Amersham Health from 2000 to 2004. He has also been the director of disease science research for Glaxo Wellcome. Clarke was a practicing academic physician for 15 years with a specialty in pediatric critical care and pediatric anesthesiology, and received an MD and MS in physiology and pharmacology from Duke University.


Cisbio announced that Mark Schmeizl has been named national sales director of Cisbio’s US division.

Prior to joining Cisbio, Schmeizl served as Northeast district sales manager at Affymetrix. Before that, he spent eight years at the Packard Instrument Company, where he held several senior-level marketing and sales positions, including marketing manager and senior product manager within the company’s Microplate Detection Systems division.


Bernard Questier has left the management board of Evotec OAI, the company said last week. Evotec said that Questier departs from the position of chief business officer to “pursue new entrepreneurial challenges.” Evotec also said it will not refill the position on the board.


Protedyne has appointed Anthony Martin to its board of directors.

Martin previously served as chairman, president, and CEO of Molecular Probes, where he was responsible for setting the company’s business strategy and increasing profits by 20 percent per year, Protedyne said. Martin had also previously served as president of the molecular biology division of Invitrogen, before it acquired Molecular Probes.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.